慢性鼻窦炎伴鼻息肉患者中度普利尤单抗处方的真实世界预测因素
本研究为单机构回顾性队列研究,纳入2015至2023年因慢性鼻窦炎伴鼻息肉(CRSwNP)接受内镜鼻窦手术(ESS)的299例患者,其中70例(23.4%)术后被处方度普利尤单抗。单因素及多因素逻辑回归显示,哮喘、阿司匹林加重性呼吸系统疾病(AERD)、过敏性鼻炎、组织嗜酸性粒细胞升高、术后3个月SNOT-22评分较高及鼻黏液IL-5、IL-13水平升高与度普利尤单抗处方相关。
要点
- 299例CRSwNP术后患者中70例(23.4%)被处方度普利尤单抗。
- 哮喘、AERD、过敏性鼻炎及组织嗜酸性粒细胞升高预测度普利尤单抗处方。
- 鼻黏液IL-5和IL-13升高及术后3个月SNOT-22较高与处方相关。
核心结论
- 哮喘、AERD、过敏性鼻炎以及组织嗜酸性粒细胞、IL-5和IL-13水平升高可预测CRSwNP患者的度普利尤单抗处方。
- 这些因素可作为临床和炎症生物标志物,并有助于向患者说明预期的疾病轨迹。
研究设计与样本
- 单机构回顾性队列研究,纳入2015年至2023年间因CRSwNP接受内镜鼻窦手术的患者。
- 从患者记录中提取人口学资料、合并症、22项鼻窦结局测试(SNOT-22)评分及度普利尤单抗处方日期。
- 采用多重珠阵列法测量术中鼻黏液细胞因子水平。
- 采用单因素逻辑回归分析确定与度普利尤单抗处方相关的因素,并采用多因素逻辑回归校正手术日期。
主要发现
- 共纳入299例CRSwNP患者,其中70例(23.4%)术后被处方度普利尤单抗。
- 单因素分析中,哮喘(OR 2.304)、AERD(OR 3.375)、组织嗜酸性粒细胞升高(OR 1.005)、术后3个月SNOT-22评分较高(OR 1.027)、鼻黏液IL-5升高(OR 1.128)和IL-13升高(OR 1.213)与度普利尤单抗处方相关。
- 校正手术日期后,相关因素包括哮喘(OR 2.444)、AERD(OR 3.750)、过敏性鼻炎(OR 1.833)、组织嗜酸性粒细胞升高(OR 1.005)、术后3个月SNOT-22评分较高(OR 1.028)、IL-5升高(OR 1.123)和IL-13升高(OR 1.202)。
临床怎么用
- 作者认为,哮喘、AERD、过敏性鼻炎及组织嗜酸性粒细胞、IL-5和IL-13水平升高可作为临床和炎症生物标志物,并有助于向患者说明预期的疾病轨迹。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite increasing dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP), little is known about the factors influencing its use in real-world practice. We aimed to identify factors that may predict dupilumab prescription in CRSwNP patients who have undergone endoscopic sinus surgery (ESS). METHODS: A single-institution, retrospective cohort study of patients who underwent ESS for CRSwNP between 2015 and 2023 was conducted. Demographics, comorbidities, 22-item sinonasal outcome test (SNOT-22) scores, and dupilumab prescription date were extracted from patient records. Intraoperative nasal mucus cytokine levels were measured using a multiplex bead assay. Univariate logistic regression analysis was performed to identify factors associated with dupilumab prescription, and multivariate logistic regression was used to adjust for surgery date. RESULTS: A total of 299 CRSwNP patients were included, including seventy (23.4%) who were prescribed dupilumab postoperatively. Patients were more likely to be prescribed dupilumab if they had asthma (odds ratio [OR] 2.304), aspirin-exacerbated respiratory disease (AERD, OR 3.375), elevated tissue eosinophils (OR 1.005), and higher 3-month postoperative SNOT-22 scores (OR 1.027). Patients prescribed dupilumab also had greater odds of having elevated mucus interleukin (IL)-5 (OR 1.128) and IL-13 (OR 1.213). When adjusting for surgery date, associated factors included: asthma (OR 2.444), AERD (OR 3.750), allergic rhinitis (OR 1.833), higher tissue eosinophils (OR 1.005), elevated 3-month SNOT-22 scores (OR 1.028), and higher IL-5 (OR 1.123) and IL-13 (OR 1.202) levels. CONCLUSION: Asthma, AERD, allergic rhinitis, and elevated tissue eosinophil, IL-5, and IL-13 levels are predictive of dupilumab prescription in CRSwNP patients. These may serve as clinical and inflammatory biomarkers and can aid in counseling patients about expected disease trajectory.
引用
- Dorismond C, Krysinski MR, Trivedi Y, et al. Real-world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2024. PMID: 39535333. doi:10.1002/alr.23483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。